 | |
| Names | |
|---|---|
| IUPAC name (4S,5aS,8S,8aR)-N-{(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl}-4-(2-methylpropyl)-3,4,5,5a,6,7,8,8a-octahydro-2H-oxepino[2,3-c]pyrrole-8-carboxamide | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider | |
| |
| |
| Properties | |
| C22H39ClN2O6S | |
| Molar mass | 495.07 g·mol−1 |
| Related compounds | |
Related compounds | Cresomycin |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Iboxamycin is a syntheticlincosamide oroxepanoprolinamideantibiotic. It binds to the bacterialribosome in bothGram-negative andGram-positive bacteria and it has been found to effective againstbacteria which are resistant to other antibiotics that target the large ribosomal subunit. It was developed by combining anoxepanoproline unit with the aminooctose residue ofclindamycin.[1]
Iboxamycin is effective againstESKAPE bacteria,methicillin-resistant Staphylococcus aureus (MRSA),Enterococcus,Clostridioides difficile,[1] andListeria monocytogenes,[2] indicating an extendedspectrum when compared to clindamycin.[1]Isotopic labeling of iboxamycin withtritium indicated that it binds 70 times more tightly to the ribosome than clindamycin.[3]
Iboxamycin can be administered orally and is safe when administered to mice.[1] It is abacteriostatic antibiotic.[1]
 | This systemicantibiotic-related article is astub. You can help Wikipedia byexpanding it. |